Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents

自噬调节剂作为新型广谱抗感染剂

• 批准号: 9893808
• 负责人: HERBERT W VIRGIN
• 金额: $ 738.13万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-15 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9893808
• 关键词: Animal Model; Anti-Infective Agents; Antibiotics; Autophagocytosis; Award; BCL2 gene; Bacterial Infections; Biomedical Research; Biotechnology; Body part; Cell physiology; Chemicals; Chemistry; Clinical; Clinical Trials; Collaborations; Communicable Diseases; Complex; Data; Development; Disease Outbreaks; Drug Controls; Drug Targeting; Drug resistance; Engineering; Equilibrium; Funding; Genes; Goals; Host Defense; Immunity; Immunology; Industry; Infection; Infection Control; Inflammation; Institutes; Intervention; Knowledge; Letters; Medical; Medicine; Microbiology; Multidrug-Resistant Tuberculosis; Multiple Bacterial Drug Resistance; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Norovirus; Organism; Participant; Pathogenesis; Pathologic; Pathway interactions; Peptides; Pharmaceutical Preparations; Phylogenetic Analysis; Productivity; Proteins; Proteomics; Regulation; Research Personnel; Research Project Grants; Resistance; Resources; Risk; Role; Salmonella; Science; Series; System; Taxonomy; Technology; Therapeutic; Time; Toxin; Toxoplasma gondii; Translational Research; Tuberculosis; United States National Institutes of Health; Virus; Work; antimicrobial; antimicrobial resistant pathogen; base; cost; design; feasibility trial; improved; in vivo; infectious disease model; innovation; medical countermeasure; nanomolar; novel; novel strategies; pathogen; prevent; priority pathogen; programs; public health priorities; screening; small molecule; translational research program; whole genome

Program Summary – Overview: The goal of this Center of Excellence for Translational Research (CETR) Program is to develop host-directed broad-spectrum anti-infective agents against NIAID priority pathogens by targeting the autophagy pathway. The most common approach for treating infectious diseases is to target pathogen-encoded proteins. However, pathogens can evolve resistance, and the spectrum of many clinically used anti-infective agents is restricted to taxonomically-related organisms. The use of host-directed anti-infective therapies offers several potential advantages to treating infectious diseases; including (1) the ability to target taxonomically-diverse pathogens; (2) decreased potential for promoting the emergence of drug-resistant organisms; and (3) the possibility of developing single compounds that target multiple pathogens, thereby decreasing the financial and regulatory barriers for developing anti-infective agents. Moreover, broad-spectrum host-directed therapeutics, once approved for clinical use against more common agents (in which clinical trials are feasible), can be deployed for emerging pathogens, new outbreaks, and pathogens engineered with ill intent. Proof-of-principle of this approach – namely, the development of effective host-directed broad-spectrum anti-infective therapeutics – could have a dramatic impact on how we treat and prevent infectious diseases. In recent years, extensive data have emerged (from our group of CETR investigators and others) indicating that degradative autophagy and autophagy-related (ATG) gene-dependent functions in immunity are crucial in host defense against taxonomically diverse pathogens. Furthermore, we and others showed that autophagy augmentation is safe and beneficial in animal models of infectious diseases. Therefore, the development of compounds that enhance autophagy and ATG gene- dependent immunity represents an attractive strategy for host-directed broad-spectrum anti-infective therapeutics. This new application has evolved from a currently funded, highly successful CETR Program entitled “Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents”. The goal of both the currently funded Program and this new proposal is to generate autophagy pathway-directed compounds that are active against a range of taxonomically-unrelated pathogens (selected based on priority status and medical need). To accomplish our goals, we will pursue a strategy that advances our current therapeutic leads and validates new targets to expand our discovery pipeline. We will accomplish our goals through five research projects entitled: RP1: Targeting Beclin 1 complexes for broad-spectrum anti-infective therapeutics. RP2: Targeting genes and pathways for autophagy-dependent inhibition of bacterial infection. RP3: Targeting Atg gene-dependent immunity for novel anti-infective therapeutics. RP4: Harnessing autophagy to treat tuberculosis. RP5: Chemical proteomic discovery of small-molecule probes for autophagy proteins. PHS 398/2590 (Rev. 06/09) Page

项目摘要-概述：该翻译研究卓越中心的目标 (CETR)计划是开发针对NIAID的宿主定向广谱抗感染药物 通过以自噬途径为靶点优先选择病原体。治疗感染性疾病最常用的方法 疾病是以病原体编码的蛋白质为靶点。然而，病原体可以进化出抗药性，而 许多临床使用的抗感染药物仅限于分类学上相关的生物体。它的用途 宿主导向的抗感染疗法为治疗传染病提供了几个潜在的优势； 包括(1)针对分类上不同的病原体的能力；(2)促进 耐药生物的出现；以及(3)开发靶向单一化合物的可能性 多种病原体，从而减少了开发抗感染药物的资金和监管障碍 探员们。此外，广谱宿主导向疗法，一旦被批准用于临床，对更多 普通制剂(在临床试验可行的情况下)，可用于新出现的病原体、新的疫情、 以及恶意设计的病原体。这一方法的原则证明--即开发 有效的宿主导向的广谱抗感染疗法-可能对 我们如何治疗和预防传染病。近年来，大量数据涌现(来自我们的 CETR调查组和其他人)表明降解性自噬和自噬相关(ATG) 免疫中的基因依赖功能在宿主防御分类上不同的病原体方面是至关重要的。 此外，我们和其他人表明，自噬增强是安全和有益的动物模型。 传染病。因此，增强自噬和ATG基因的化合物的开发- 依赖免疫是一种诱人的宿主导向广谱抗感染策略 治疗学。这一新的申请是从目前资助的、非常成功的CETR计划演变而来的 题为《作为新型广谱抗感染剂的自噬调节剂》。目前双方的目标都是 资助的计划和这项新的提议是产生自噬途径导向的活性化合物 针对一系列分类上无关的病原体(根据优先地位和医疗需求选择)。至 为了实现我们的目标，我们将采取一种战略，推进我们目前的治疗线索，并验证新的 目标是扩大我们的发现管道。我们将通过五个研究项目来实现我们的目标，这些项目分别是： RP1：将Beclin 1复合体作为广谱抗感染治疗的靶点。 RP2：针对依赖自噬抑制细菌感染的基因和途径。 RP3：针对ATG基因依赖的免疫，用于新的抗感染疗法。 RP4：利用自噬治疗结核病。 RP5：自噬蛋白小分子探针的化学蛋白质组学发现。 PHS 398/2590(06/09版)页面